Exscientia to present new preclinical data for ai-designed lsd1 and malt1 inhibitors at esmo 2023

Oxford, england--(business wire)--exscientia plc (nasdaq: exai) today announced two abstracts to be presented at the upcoming european society for medical oncology (esmo) congress 2023 from october 20-24, 2023 in madrid, spain. “we are excited to share new preclinical data on our precision-designed lsd1 and malt1 inhibitors, which we introduced to our oncology pipeline earlier this year,” said professor andrew hopkins frs fmedsci, founder and chief executive officer of exscientia. “we believe t.
EXAI Ratings Summary
EXAI Quant Ranking